All In Biotech

Drug Trial Radar · NCT06696755

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

A Phase 2, Multicenter, 6-Week, Double Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Bipolar Depression

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

195

Planned (sponsor's estimate)

Start

Feb 3, 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. This study will assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder. Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to a placebo. Around 195 adult participants with bipolar I or II disorder will be enrolled in approximately 35 sites across the United States of America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 4-week safety follow-up period. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Bipolar I Disorder
  • Bipolar II Disorder

Interventions

  • IcalcaprantDrug

    Oral Capsules

  • Placebo for IcalcaprantDrug

    Oral Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total scoreTime frame: Up to approximately Week 6
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 10 weeks

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Huntsville Regional Medical Campus /ID# 272951

    Huntsville, Alabama · Recruiting

  • Chandler Clinical Research Trials /ID# 274500

    Chandler, Arizona · Recruiting

  • Del Sol Research Management - East Tanque Verde Road - Tucson /ID# 279767

    Tucson, Arizona · Recruiting

  • Sanro Clinical Research Group /ID# 279462

    Bryant, Arkansas · Recruiting

  • Advanced Research Center /ID# 272828

    Anaheim, California · Recruiting

  • Collaborative Neuroscience Research - Garden Grove /ID# 271917

    Garden Grove, California · Recruiting

  • Catalina Research Institute /ID# 272831

    Montclair, California · Recruiting

  • Excell Research /ID# 272854

    Oceanside, California · Recruiting

  • Pacific Neuropsychiatric Specialists - Orange /ID# 273118

    Orange, California · Recruiting

  • Schuster Medical Research Institute /ID# 272848

    Sherman Oaks, California · Recruiting

  • Sarkis Clinical Trials- Gainesville /ID# 272861

    Gainesville, Florida · Recruiting

  • CenExel Hollywood FL /ID# 273101

    Hollywood, Florida · Recruiting

  • Accel Research Sites Network - St. Pete /ID# 272962

    Largo, Florida · Recruiting

  • Apg Research /ID# 272925

    Orlando, Florida · Recruiting

  • Combined Research Orlando /ID# 279458

    Orlando, Florida · Recruiting

  • Clinical Research Center Of Florida /ID# 278790

    Pompano Beach, Florida · Recruiting

  • St. Johns Center for Clinical Research - Saint Augustine Location /ID# 279465

    Saint Augustine, Florida · Recruiting

  • Neuroscience Institute - West Palm Beach /ID# 272922

    West Palm Beach, Florida · Recruiting

  • Georgia Psychiatric Consultants and Advanced Discovery Research /ID# 279438

    Atlanta, Georgia · Recruiting

  • Pillar Clinical Research - Chicago /ID# 272823

    Chicago, Illinois · Recruiting

  • Amr Conventions Research /ID# 272867

    Warrenville, Illinois · Recruiting

  • Saint Charles Psychiatric Associates /ID# 279239

    Saint Charles, Missouri · Recruiting

  • Manhattan Behavioral Medicine /ID# 279769

    New York, New York · Recruiting

  • University Of Cincinnati Medical Center /ID# 274160

    Cincinnati, Ohio · Recruiting

  • The Ohio State University /ID# 272954

    Columbus, Ohio · Recruiting

  • Sooner Clinical Research /ID# 272856

    Oklahoma City, Oklahoma · Recruiting

  • Community Clinical Research - Cross Park Drive /ID# 272940

    Austin, Texas · Recruiting

  • Elixia - Houston /ID# 279200

    Houston, Texas · Recruiting

  • Mind Matters Psychiatry /ID# 273536

    Missouri City, Texas · Recruiting

  • Pillar Clinical Research - Richardson /ID# 272821

    Richardson, Texas · Recruiting

  • Family Psychiatry Of The Woodlands /ID# 275177

    The Woodlands, Texas · Recruiting

  • Northwest Clinical Research Center /ID# 272847

    Bellevue, Washington · Recruiting

  • Core Clinical Research /ID# 272955

    Everett, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.